DURHAM,
N.C. and WARSAW,
Ind., June 12, 2024 /PRNewswire/ -- RevelAi
Health and Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a
global medical technology leader, today announced a multi-year
co-marketing agreement to commercialize generative artificial
intelligence (AI)-powered engagement solutions that advance
value-based orthopedic care and health equity. During the
multi-year agreement, Zimmer Biomet will commercialize RevelAi
Health's patient care-management platform, care team dashboard for
providers, and any future products or services.
"Leveraging generative AI to streamline clinical care workflows
while addressing socio-demographic disparities is a unique
opportunity to drive equitable value-based outcomes," said
Christian Péan MD, MS, CEO of RevelAi Health and an orthopedic
trauma surgeon at Duke University
School of Medicine. "Our AI-enabled asynchronous care model
delivers personalized, timely, and effective patient care while
reducing clinician burnout. Our collaboration with Zimmer Biomet is
a significant step towards ensuring that every patient receives the
care they deserve."
RevelAi Health is a software as a service (SAAS) health
technology company that specializes in cutting-edge generative AI
population health solutions. RevelAi Health's clinician-validated
large language model helps healthcare providers transition
seamlessly to value-based care, meeting essential CMS (Centers for
Medicare & Medicaid Services) requirements, including Patient
Reported Outcome measures and Social Drivers of Health (SDOH)
Screening.
RevelAi Health also offers a first-of-its-kind patient care
management system, leveraging text messaging and clinician-guided
voice agent to streamline care workflows that enhance patient
engagement.
"Making orthopedic care more accessible and providing innovative
solutions that meet both the clinical and social needs of the
communities we serve are key to improving health outcomes," said
Edmond Davis, Senior Director-Health
Equity at Zimmer Biomet. "Teaming up with RevelAi allows us
to combine our innovative technologies and shared objective to
address the needs of underserved and vulnerable populations, while
helping clinicians optimize value-based outcomes."
For more information about this partnership and the technologies
involved, please visit www.revelaihealth.com and
www.zimmerbiomet.com/en/value-based-care.html.
About RevelAi Health
RevelAi Health is a leader in deploying artificial intelligence
to enhance patient outcomes while reducing clinician burnout in
healthcare. By focusing on AI-driven clinical workflows and
addressing social drivers of health, RevelAi Health aims to deliver
equitable, value-based healthcare solutions for diverse patient
populations.
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a
comprehensive portfolio designed to maximize mobility and improve
health. We seamlessly transform the patient experience through our
innovative products and suite of integrated digital and robotic
technologies that leverage data, data analytics and artificial
intelligence.
With 90+ years of trusted leadership and proven expertise,
Zimmer Biomet is positioned to deliver the highest quality
solutions to patients and providers. Our legacy continues to come
to life today through our progressive culture of evolution and
innovation.
For more information about our product portfolio, our operations
in 25+ countries and sales in 100+ countries or about joining our
team, visit www.zimmerbiomet.com or follow on LinkedIn at
www.linkedin.com/company/zimmerbiomet or X / Twitter at
www.twitter.com/zimmerbiomet.
RevelAi Health:
Media
Kim Truong
kim@revelaihealth.com
Zimmer Biomet:
Media
Heather
Zoumas-Lubeski
445-248-0577
heather.zoumaslubeski@zimmerbiomet.com
Investors
Zach
Weiner
908-591-6955
zach.weiner@zimmerbiomet.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/revelai-health-and-zimmer-biomet-announce-exclusive-multi-year-co-marketing-agreement-to-advance-value-based-care-and-health-equity-through-ai-powered-technology-302170335.html
SOURCE RevelAi Health